ViiV Healthcarehas filed for US and EU approval of a two-drug regimen for HIV consisting of its integrase inhibitor dolutegravir and Janssen Inc.'s non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant) in a single tablet. If approved, this will be first two-drug regimen for the maintenance treatment of HIV-1 infection, and will offer patients an NRTI-free option.
ViiV/Janssen Forge Two-Drug Future For HIV With SWORD Filings
The battle of the HIV giants ViiV Healthcare and Gilead Sciences continues with the first filing for a two-drug regimen for use against HIV infection in the US and EU.
More from New Products
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The German group is paying $3.9bn to get hold of the US firm and its two approved products.
• By
Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.